Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

2019 ◽  
Author(s):  
Vivek Subbiah ◽  
Minal Barve ◽  
Nicholas O. Iannotti ◽  
Martin Gutierrez ◽  
David C. Smith ◽  
...  
Keyword(s):  
Growth Factor ◽  
Combination Therapy ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Advanced Malignancies

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2501-2501 ◽  
Author(s):  
Rastislav Bahleda ◽  
Rodrigo Dienstmann ◽  
Barbara Adamo ◽  
Anas Gazzah ◽  
Jeffrey R. Infante ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Solid Tumors ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Advanced Solid Tumors ◽  
Fibroblast Growth ◽  
Phase 1 Study

A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2620-2620 ◽  
Author(s):  
Hendrik-Tobias Arkenau ◽  
Matilde Saggese ◽  
Antoine Hollebecque ◽  
Alastair Mathewson ◽  
Charlotte Rose Lemech ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Expansion Cohort
Sign in / Sign up

Export Citation Format

Share Document